Navigator vê lucro cair para 65 milhões e pede apoios face aos custos da energia

[pmlcastanho]

https://toregem.co.jp/en/archives/10498

[pmlcastanho]

https://toregem.co.jp/en/archives/10496

[pmlcastanho]

https://toregem.co.jp/en/archives/10477

[pmlcastanho]

Toregem Biopharma is a Japanese biotechnology startup founded in May 2020 as a spinoff of Kyoto University. The company is developing the world's first drug designed to naturally regenerate teeth.
How Does the Technology Work?
• Protein Blocking: The treatment utilizes a neutralizing antibody against the USAG-1 protein. This protein acts as a molecular switch that suppresses tooth growth.
• Stimulating Tooth Buds: By blocking this protein, the drug stimulates existing tooth germs—buds that are otherwise inactive or degenerate in the human body—allowing a new tooth to grow.
• Intended Application: The research focuses on patients with congenital tooth agenesis (anodontia) as well as adults who have lost teeth due to severe cavities or injuries.
Current Status and Commercialization
• Clinical Trials: The company has advanced into human clinical trials for its experimental drug, designated TRG-035, to thoroughly evaluate its safety and efficacy.
• Launch Timeline: Toregem BioPharma projects that the medication could be commercially available by 2030. The initial rollout is planned for pediatric patients with congenital conditions, with plans to expand to the general public later.